Antimicrobial Efficacy of Cefoperazone-Salbactam Plus Tigecycline versus Cefoperazone-Salbactam Against Respiratory Pathogens and Their Effect on Laboratory Indices
DOI:
https://doi.org/10.51253/pafmj.v73i3.10546Keywords:
Cefoperazone, Infections, Respiratory, Sulbactam, TigecyclineAbstract
Objective: To compare the antimicrobial efficacy of cefoperazone plus tigecycline versus cefoperzone and their effect on
biochemical indices.
Study Design: Quasi-experimental study.
Place and Duration of Study: Department of Pathology, Rehman Medical Institute, Peshawar Pakistan, Nov 2022 to May 2023.
Methodology: Patients of either gender with age >20 years having intensive care unit stay of >72 hours having clinical and radiological evidence of hospital acquired respiratory infection were included in the trial. A non-randomized convenience sampling technique was employed. Group CT patients received a combination of cefoperazone-sulbactam plus tigecycline intravenously while Group C participants received only cefoperazone-salbactam. Demographics, inflammatory markers,pathogens, treatment effectivity were recorded.
Results: Mean age of participants in Group CT was 57.59±6.08 years as compared to 56.37±6.87 years in Group C. Pseudomonas aeruginosa was the most common pathogen identified in 30(23.8%) patients. CRP, WBC’s and PCT was significantly reduced after antibiotic treatment in both groups with a p-value of <0.01 and significant decrease in the serum levels of these markers was observed in Group CT as compared to Group C with a p-value of <0.05. Overall, the treatment effectivity was observed in 57(90.5%) participants in Group CT as compared to 46(73%) in Group C.
Conclusion: Cefoperazone-salbactam plus tigecycline offers superior antimicrobial activity as compared to cefoperazonesulbactam in patients with hospital acquired respiratory tract infections.